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Nischarin, a novel intracellular protein, was originally
identified as a binding partner for the a5b1 integrin.
Here we show that Nischarin also interacts with members
of the PAK family of kinases. The amino terminus of
Nischarin preferentially binds to the carboxy-terminal
domain of PAK1 when the kinase is in its activated con-
formation. Nischarin binding to PAK1 is enhanced by
active Rac, with the three proteins forming a complex,
while expression of the a5b1 integrin also increases the
Nischarin/PAK1 association. Interaction with Nischarin
strongly inhibits the ability of PAK1 to phosphorylate
substrates. This effect on PAK kinase activity closely
parallels Nischarin’s ability to inhibit cell migration.
Conversely, reduction of endogenous levels of Nischarin
by RNA interference promotes cell migration. In addition,
PAK1 and Nischarin colocalize in membrane ruffles, struc-
tures known to be involved in cell motility. Thus,
Nischarin may regulate cell migration by forming inhibi-
tory complexes with PAK family kinases.
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Introduction
Cell migration is a complex process that requires the spatial
and temporal coordination of many proteins. During migra-
tion, cells extend membrane protrusions, establish adhesive
contacts, exert force to move the cell body, and ultimately
retract the rear portion of the cell. These events involve
actin filament extension regulated by the Arp2/3 complex,
as well as actinomyosin-mediated contractility (Pollard and
Borisy, 2003). Members of the integrin family of heterodi-
meric cell surface receptors also play a key role in cell
migration. Integrins and certain associated cytosolic proteins
provide a structural linkage between the proteins of the
extracellular matrix and the actin cytoskeleton (Liu et al,
2000; Sastry and Burridge, 2000). Further, integrins help to
regulate an intricate network of signaling pathways needed
for the control of migration (Hood and Cheresh, 2002;
Juliano, 2002). Members of the Rho family of GTPases are
critically important in regulating the actin cytoskeleton
(Bishop and Hall, 2000; Ridley, 2001). However, a number
of other signaling components have been implicated in cell
migration, including focal adhesion kinase, Src, Crk, PI-3-
kinase and MAP kinases, as has been reviewed elsewhere
(Alahari et al, 2002).
The Rho family GTPases Rac and CDC42 regulate the
formation of membrane protrusions involved in motility
(Ridley, 2001). Among the key downstream effectors of
CDC42 and Rac are members of the PAK family of serine/
threonine kinases (Kumar and Vadlamudi, 2002; Bokoch,
2003). Based on their structures, PAKs have been divided
into two groups: group 1 consists of PAK1–3, while group 2
consists of PAK4–6. Group 1 PAKs have a Rac/CDC42-binding
domain and an overlapping autoinhibitory domain in the
amino terminus, and a kinase domain in the carboxy termi-
nus (Bagrodia and Cerione, 1999). Inactive group 1 PAKs
exist as autoinhibited dimers. Upon GTPase binding, PAKs
undergo a conformational change that separates the auto-
inhibitory domain from the kinase domain (Parrini et al,
2002). This induces kinase activity and autophosphorylation
at several sites, including Thr 423 in the activation loop
(Buchwald et al, 2001; Chong et al, 2001). Outside of the
kinase- and GTPase-binding domains, group 2 PAKs are quite
different from group 1 and their regulation may be distinct
(Dan et al, 2002). PAKs are primarily localized in the cyto-
plasm in resting cells; however, activated PAKs translocate to
focal adhesions and membrane ruffles (Sells et al, 2000). The
exact mechanism of PAK regulation of the actin cytoskeleton
and cell migration is not fully understood. PAKs phosphor-
ylate and inhibit myosin light-chain kinase, leading to re-
duced actinomyosin contractility (Sanders et al, 1999). In
addition, PAKs phosphorylate and activate LIM kinase lead-
ing to increased phosphorylation of cofilin, which plays a role
in actin severing (Edwards et al, 1999) and regulation of actin
filament turnover (Carlier et al, 1999). However, kinase-
independent contributions of PAKs to cell motility have also
been described (Sells et al, 1999).
In addition to Rac and CDC42, group 1 PAKs also associate
with a variety of other proteins including Nck, filamin,
paxillin, Merlin, p41-Arc, G-protein bg subunits, Cool/Pix
exchange factors, and certain cytoplasmic tyrosine kinases
(Manser et al, 1998; Xia et al, 2001; Brown et al, 2002; Feng
et al, 2002; Kumar and Vadlamudi, 2002; Vadlamudi et al,
2002; Bokoch, 2003; Kissil et al, 2003; Vadlamudi et al, 2004).
Among the negative regulators of PAK are several kinases,
including protein kinase A (Howe and Juliano, 2000), while
the phosphatases PP2A and POPX1/2 dephosphorylate PAK
and thus inhibit its activity (Koh et al, 2002; Kumar and
Vadlamudi, 2002). In summary, PAKs interact with the cyto-
skeleton in several ways that influence cell motility; conver-
sely, a number of proteins associate with PAKs and regulate
their functions.
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One important way in which integrins influence cellular
behavior is by the interaction of their cytoplasmic tails with
intracellular proteins (Liu et al, 2000). Many investigators
have sought proteins that bind to integrin tail regions
and might thus be downstream effectors. Pursuing this
approach, we identified a novel protein termed Nischarin
that interacts preferentially with the a5 cytoplasmic domain.
Overexpression of Nischarin in fibroblasts led to changes in
cytoskeletal organization and to a profound inhibition of cell
migration (Alahari et al, 2000). Nischarin also strongly
inhibited Rac-driven cell migration and invasion of carcino-
ma cells, with the observations suggesting that Nischarin
might act primarily by affecting PAK (Alahari, 2003).
In the current report we demonstrate that Nischarin binds
selectively to PAKs via its N-terminus, with preferential
binding to the ‘open’ conformation of the kinase. Nischarin
also inhibits the ability of PAK1 to phosphorylate substrates.
The ability of Nischarin to inhibit PAK kinase activity closely
parallels its inhibition of cell migration. Further, Nischarin
and PAK1 colocalize in areas of membrane ruffling associated
with cell motility. Finally, the reduction of endogenous
Nischarin levels results in enhanced cell migration via a
process that seems to involve PAK activation. These studies
suggest that Nischarin is a key regulator of PAKs in the
context of cell migration. Further, since Nischarin also
binds the a5b1 integrin, this may provide a means for
localized control of PAK function.
Results
The N-terminal domain of Nischarin binds
to the C-terminal domain of PAK1
Previous work on the effect of Nischarin on Rac-driven cell
migration suggested a functional linkage between Nischarin
and PAKs (Alahari, 2003). To determine if the link was
physical, the ability of Nischarin and PAK1 to form intracel-
lular complexes was examined. Nischarin is a large protein
with an integrin a5-binding region as its only functionally
defined domain (Alahari et al, 2000) (see Figure 1A). To begin
to isolate the region responsible for binding PAK, Nischarin
was initially subdivided into two large domains, the N-
terminus (aa 1–802) and the C-terminus (aa 970–1354),
with the sites of truncation chosen based on a predicted
lack of secondary structure (http://www.embl-heidel-
berg.de/predictprotein/predictprotein.html). Most of the pro-
line- and alanine-rich region, residues 803–969, was not
included in either construct because truncated proteins con-
taining this region were not stable (data not shown). Cos-7
cells were transfected with Myc epitope-tagged Nischarin
constructs and V5 epitope-tagged PAK1; Nischarin was im-
munoprecipitated with anti-Myc antibody and the immuno-
precipitates were probed for associated PAK1. The presence
of PAK1 was readily detectable upon probing the immuno-
blots with the anti-V5 antibody in immunoprecipitates of full-
length Nischarin or the N-terminus, but not the C-terminus
(Figure 1B). Reciprocal immunoprecipitation of V5-PAK1
with the anti-V5 antibody co-immunoprecipitated Myc-
Nischarin or the N-terminus (Figure 1C). The unrelated
protein b-galactosidase bound neither PAK1 nor Nischarin
in these assays.
To isolate the region within the N-terminus that mediated
complex formation, further deletion analysis was performed
(Supplementary Figure 1). Thus the regions 1–415 and 416–
624 exhibited strong binding, while 625–802 exhibited weak-
er binding. Division of the 1–415 region into two separate
segments (1–217 and 218–415) disrupted PAK complex for-
mation. Thus, several regions within the Nischarin amino
terminus are able to contribute to the formation of PAK/
Nischarin complexes.
Supporting the importance of this interaction, the
Nischarin–PAK association takes place between endogenous
proteins as well as during protein overexpression. Thus
immunoprecipitation of endogenous PAK from PC12 cells
results in co-immunoprecipitation of endogenous Nischarin
(Figure 1D).
Since Nischarin interacts with the a5b1 integrin (Alahari
et al, 2000), it is important to determine if the binding of
Nischarin to PAK is affected by its interaction with integrin.
As seen in Figure 1E, overexpression of the a5 subunit
enhanced the binding of coexpressed Nischarin and PAK1.
Further, all three components were found in the Nischarin
immunoprecipitate, suggesting a simultaneous association
between PAK, a5b1 and Nischarin.
The regulatory domain of PAK1 spans residues 1–248 of its
N-terminus, while amino acids from 248 to 545 comprise the
kinase domain. To identify which region of PAK1 interacts
with Nischarin, the two domains were separately expressed
in Cos-7 cells along with full-length Myc-Nischarin. Nischarin
interacted with the kinase domain of PAK1 (248–545), but not
with the regulatory domain (Figure 2A); this was consistently
seen in reciprocal immunoprecipitations of these proteins
(Figure 2B). Since Nischarin specifically interacts with the
kinase domain of PAK1, we hypothesized that the interaction
of Nischarin with full-length PAK1 would be dependent on
the activation state of the kinase. To test this, Myc-Nischarin
was coexpressed with the PAK1 activation loop mutant V5-
PAK1-T423E; the threonine to glutamic acid substitution
mimics the phosphorylation of T423 and partially activates
the kinase (Sells et al, 1997; King et al, 2000; Chong et al,
2001). Myc-Nischarin was also coexpressed with V5-PAK1-
K299R, a kinase-dead version of the protein (Sells et al,
1997). Nischarin immunoprecipitated via its Myc tag showed
enhanced co-precipitation of PAK1-T423E, as compared to
wild-type (WT) PAK1, while co-precipitation of PAK1-K299R
was dramatically reduced (Figure 2C). These data indicate
that the activation of PAK1 facilitates its interaction with
Nischarin.
PAK and Nischarin colocalize in membrane ruffles
Since Nischarin both binds to PAK and affects cell migration,
one might anticipate that PAK and Nischarin would be found
together in subcellular compartments associated with cell
movement. To test this, rat embryonic fibroblasts were co-
transfected with GFP-Nischarin and with Myc-tagged PAK1.
Transfected cells were plated on fibronectin substrata and the
subcellular distributions of PAK1 and Nischarin were visua-
lized by confocal fluorescence microscopy. Both PAK1 and
Nischarin were widely distributed in the cytoplasm and
seemed associated with vesicular structures in the perinuc-
lear area. However, both proteins were also enriched in
membrane ruffles, and image superposition clearly indicated
regions of colocalization (Figure 3Aiii). When PAK1 mutants
were examined, it was obvious that kinase-dead K299R PAK1
failed to show significant membrane colocalization with GFP-
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Figure 1 Nischarin/PAK1 interactions. (A) Nischarin domains. Regions homologous to known protein motifs as defined by BLASTanalysis are
shown. These include the leucine-rich repeats, leucine zipper motifs, potential SH3 binding sites (PXXP) and the cytochrome P450 cysteine
heme-iron ligand signature. The integrin-binding domain (IBD) as defined in initial studies (Alahari et al, 2000) is also noted. (B, C) Nischarin’s
PAK-binding region. Cos-7 cells were cotransfected with Myc-Nischarin, Myc-Nis 1–802, Myc-Nis 970–1354, or Myc-b-galactosidase and
V5-PAK1. At 48 h after transfection, the cells were lysed and the tagged proteins were immunoprecipitated with a 1:100 dilution of monoclonal
anti-Myc or anti-V5 antibody. The blots were probed for the Myc and V5 epitopes. (D) Interaction of endogenous PAK and Nischarin. PC12 cells
were lysed in modified RIPA buffer and lysates were immunoprecipitated with an agarose-conjugated rabbit polyclonal anti-PAK1 (N20) or a
control agarose-conjugated IgG overnight at 41C. Immunoblots were probed with a monoclonal anti-Nischarin antibody or an irrelevant mAb.
(E) Effect of a5b1 on PAK/Nischarin interactions. V5-PAK1 and Myc-Nischarin were expressed in Cos-7 cells with or without coexpression of
the integrin a5 subunit. Immunoprecipitation and Western blotting were as described above.
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Nischarin (Figure 3B). By contrast, expression of the active
T423E mutant resulted in enhanced colocalization with GFP-
Nischarin (Figure 3C). Higher power images of cell protru-
sions suggested that PAK is present at the leading edge of the
protrusion, while GFP-Nischarin overlaps with PAK just
behind the edge (Figure 3Ciii0). These results show that
PAK1 and Nischarin colocalize in ruffles, cellular structures
known to be involved in cell migration, and that Nischarin
preferentially localizes with active PAK1.
Nischarin selectively inhibits PAK kinase activity
Given that Nischarin preferentially associates with activated
PAK1, we hypothesized that Nischarin may influence PAK
kinase activity. To test this, we transiently cotransfected Cos-
7 cells with V5-tagged PAK1 and with Myc-Nischarin or Myc-
b-gal. Immunoprecipitated PAK proteins were tested for their
kinase activity using myelin basic protein as a substrate. As
shown in Figure 4A, serum stimulation strongly increased
PAK kinase activity, while coexpression of full-length
Nischarin blocked the increase in PAK activity; by contrast,
coexpression of b-galactosidase had no effect. Interestingly,
full-length Nischarin was required for effective inhibition of
PAK kinase activity, whereas the amino-terminal (1–802) or
carboxy-terminal (970–1354) fragments, or other fragments
of Nischarin (data not shown) had no effect on PAK activa-
tion.
These experiments demonstrated that Nischarin blocks
serum-mediated activation of PAK1. However, they did not
distinguish between direct effects on PAK1 itself and blockade
of the signaling pathway leading to PAK activation. To
investigate whether Nischarin acts directly on PAK, a con-
stitutive, partially activated form of PAK1 (PAK1-T423E) was
used in kinase assays. As seen in Figure 4B, the kinase
activity of immunoprecipitated PAK1-T423E was inhibited
by Nischarin. Similar to the results with WT PAK1, the
activity of T423E was inhibited only by full-length
Nischarin, but not by truncated forms of Nischarin (data
not shown). Thus Nischarin seems to inhibit directly the
ability of PAK1 to phosphorylate substrates.
To determine whether the effect of Nischarin on PAK
kinase activity is selective, we examined the action of
Nischarin on c-Jun kinase (JNK) (Bishop and Hall, 2000).
Rac strongly increased JNK activity, but Nischarin had no
inhibitory effect on this process (Figure 4C). This indicates
that Nischarin selectively inhibits PAK activity without affect-
ing other Rac-driven kinases.
As an initial approach to understanding the mechanism by
which Nischarin inhibits PAK1, we tested whether Nischarin
blocks the autophosphorylation of PAK1 that is part of its
activation process or, alternatively, whether Nischarin could
serve as a competitive substrate for PAK1. As seen in
Figure 4D, overexpression of Nischarin inhibited PAK auto-
kinase activity in parallel with inhibition of substrate phos-
phorylation. Further, use of an antibody that recognizes the
phosphorylated form of one of the autoactivation sites on
PAK1 demonstrated that phosphorylation at this site was
inhibited by Nischarin overexpression (Supplementary
Figure 2). These observations suggest that Nischarin can
inhibit the activation of PAK1. By contrast, we found little
evidence that Nischarin could serve as a substrate for PAK1
and thus block phosphorylation of other substrates by com-
petition. For example, partially purified, in vitro expressed
Figure 2 The Nischarin-binding domain of PAK1. (A, B) Nischarin interacts with the kinase domain of PAK1. Full-length V5-PAK1, V5-PAK-1-
248 or V5-PAK1-248-545 was cotransfected with Myc-Nischarin. The extracts were immunoprecipitated with the anti-V5 (A) or anti-Myc (B)
antibodies and the immunoprecipitates were immunoblotted for the indicated epitopes. (C) Nischarin interacts with active PAK1. Cos-7
cells were cotransfected with the Myc-Nischarin or Myc-b-galactosidase and V5-PAK1, constitutively active V5-PAK1-T423E, or kinase-
dead V5-PAK1-K299R. After transfection, the Myc-tagged proteins were immunoprecipitated and the blots probed with anti-Myc and anti-V5
antibodies.
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Nischarin was not significantly phosphorylated by active
GST-PAK1 under conditions where myelin basic protein was
abundantly phosphorylated (Supplementary Figure 3). This
suggests that Nischarin is a poor substrate for PAK1 and thus
unlikely to compete with other substrates.
Nischarin levels modulate PAK-induced cell migration
As discussed above, PAK has been shown to play an impor-
tant role in cell migration. Nischarin inhibits both cell migra-
tion (Alahari et al, 2000; Alahari, 2003) and PAK kinase
activity; thus, it is important to understand the relationship
Figure 3 Colocalization of PAK and Nischarin in membrane ruffles. Rat embryonic fibroblasts were transiently transfected with GFP-Nischarin
and (A) Myc-PAK1 or (B) Myc-K299R-PAK1 or (C) Myc-T423E-PAK1. After serum starvation, the cells were replated on fibronectin-coated
coverslips for 45 min, stained with anti-Myc antibody and observed using an Olympus confocal fluorescence microscope with a  60 lens. (A)
GFP fluorescence is shown in green (i); anti-Myc-PAK1 staining is shown in red (ii); an overlay image is shown in (iii) where yellow indicates
colocalization of Nischarin and PAK1 (B, C) Similar images of GFP-Nischarin and (B) Myc-K299R-PAK1 or (C) Myc-T423E-PAK1. Images i0–iii0
show enlargements of part (yellow box) of the i–iii images for Myc-T423E-PAK1 (white arrowheads point to colocalization of PAK and
Nischarin in ruffles; blue arrowheads show PAK staining at the far edges of the cell). Scale bar: 20mm.
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between these two actions of Nischarin. To investigate this
issue, we examined the effects of Nischarin and its fragments
on migration stimulated by an active form of PAK1 (T423E).
Thus, CHO B2 a27 cells (which express human alpha 5
integrin) were transfected with PAK1-T423E or with kinase-
dead PAK (PAK1-K299R), and were cotransfected with
Nischarin or the N-terminal (1–802) or C-terminal (970–
1354) domains of Nischarin. Subsequent to transfection,
cell migration assays were performed. As shown in
Figure 5A, PAK1-T423E stimulated migration in the CHO
cells, and this was strongly inhibited by overexpression of
Nischarin. Interestingly, the kinase-dead version of PAK1 did
Figure 4 Kinase activity assays. (A) Nischarin inhibits serum-stimulated PAK activity. Immunoprecipitates were made from Cos-7 cells
transfected with the indicated constructs. The cells shown in lanes 2–5 were stimulated with serum. Upper panel: the immunoprecipitates were
used in in vitro kinase assays using myelin basic protein (MBP) as a substrate; middle panel: the lysates were blotted with anti-Myc antibody;
lower panel: the lysates were blotted with anti-V5 antibody. (B) Nischarin inhibits T423E PAK activity. Immunoprecipitates were made from
Cos-7 cells transfected with the indicated constructs. Upper panel: the immunoprecipitates were used in in vitro kinase assays as above; middle
panel: the lysates were blotted with anti-Myc antibody; lower panel: the lysates were blotted with anti-V5 antibody. (C) Nischarin does not
affect JNK activity. Cell lysates made from Cos-7 cells transfected with the indicated combinations of pAX vector, HA-JNK1, pAX-RacQ61L and
Myc-Nischarin were immunoprecipitated with anti-HA antibody and the immunoprecipitates were used to detect JNK activation as described
(Alahari, 2003). Upper panel: phosphorylation of GST-JUN; lower panel: immunoblotting with anti-HA antibody. (D) Nischarin inhibits
autophosphorylation of PAK1. This assay was similar to that of (A) except that the kinase assay was for 5 min and the gel was run to allow
visualization of the PAK band. Upper panel: phosphorylation of V5-PAK1 and MBP; middle panel: PAK levels in the IP; lower panel: Nischarin
or b-gal levels in the lysate.
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not stimulate migration in this system. Consistent with our
data on kinase inhibition, only full-length Nischarin was able
to inhibit PAK1-T423E-driven migration (Figure 5A), while
the N- or C-terminal domains had no effect. Thus there is a
close parallel between Nischarin’s ability to block PAK kinase
activity and its ability to inhibit PAK-driven cell migration.
Since overexpression of Nischarin inhibits PAK-driven cell
migration, we wished to see if reducing endogenous levels of
Nischarin would affect cell motility. Thus, PC12 cells (which
have endogenous Nischarin) were transfected with an siRNA
oligonucleotide targeted to Nischarin, or with a control
oligonucleotide. The migratory ability of these cells was
then tested. The anti-Nischarin siRNA, but not the control
siRNA, caused a substantial reduction in the amount of
endogenous Nischarin (Figure 5B). The anti-Nischarin
siRNA, but not the control, also dramatically stimulated cell
migration (Figure 5C). Interestingly, coexpression of a PAK
fragment comprising the autoinhibitory domain significantly
reversed the increase in migration caused by the anti-
Nischarin siRNA. This domain can block PAK kinase activity,
suggesting that the stimulation of migration caused by the
siRNA was due to increased PAK activity. To pursue this
further, we treated PC12 cells with anti-Nischarin siRNA or
control siRNA, immunoprecipitated the endogenous PAK and
tested its kinase activity. As seen in Figure 5D, transfection
with anti-Nischarin siRNA caused an increase in the activity
of endogenous PAK. It should be noted that only a fraction of
the cells were transfected, so that only a portion of the total
pool of PAK was affected by siRNA-mediated modulation of
Nischarin. In summary, these results suggest that reducing
levels of endogenous Nischarin can promote cell motility by
permitting enhanced activation of PAK.
The PAK/Nischarin interaction is modulated by active
Rac and requires the open form of PAK
Since the above observations suggest that the Nischarin–PAK
interaction significantly affects cell migration behavior, we
Figure 5 Effects of Nischarin on PAK-induced migration. (A)
Overexpression of full-length Nischarin inhibits PAK-driven migra-
tion. CHO B2-a27 cells were transiently transfected with vector
alone, with V5-PAK1-T423E plus Myc-vector, full-length Myc-
Nischarin, Myc-Nischarin (1–802) or Myc-Nischarin (970–1354).
Other cells were transfected with V5-PAK1-K299R plus Myc-
Nischarin or vector control. A b-gal plasmid was also used to
mark all transfectants. Cells were plated in transwells, and the b-
gal-expressing cells migrating through the transwells were counted.
(B) Effects of siRNA on Nischarin levels. PC12 cells were transfected
with pcDNA-CD4 and 150 nM anti-rat Nischarin siRNA or control
siRNA (anti-human MDR1). At 48 h after transfection, the CD4-
positive cells were selected with anti-CD4-coated Dynabeadss. The
cells were lysed and equal amounts of protein were used for SDS–
PAGE. An anti-Nischarin antibody was used for Western blotting.
Two separate lanes are shown for cells treated with siRNA for
Nischarin. (C) Effects of siRNA on cell migration. The haptotactic
migration of PC12 cells was examined using a Transwell assay.
Membrane inserts were coated with 10mg/ml collagen. Cells were
transfected with 150 nM anti-Nischarin siRNA or with control
siRNA, as well as with a vector expressing b-gal. Some sets of
cells were cotransfected with a construct that expresses the PAK1
autoinhibitory domain (AID). Cells were plated in transwells and
the b-gal-expressing cells migrating through the transwells were
counted. Results are the means and standard errors of six determi-
nations. (*) The difference between the Nis siRNA and Nis
siRNAþAID samples was significant at the 0.01 level. (D) Effects
of siRNA on PAK activity. PC12 cells were transfected with 150 nM
Nischarin siRNA or control siRNA. At 48 h after transfection, the
cells were lysed and endogenous PAK was immunoprecipitated. The
immunoprecipitate was used in an in vitro kinase assay with MBP
as a substrate. The upper panel shows MBP phosphorylation, the
middle panel the amount of PAK in the immunoprecipitate and the
lower panel the amount of Nischarin in the lysate.
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decided to further investigate other aspects of PAK/Nischarin
binding. Binding of Rac1/CDC42 is an important step in
the activation of PAK (Buchwald et al, 2001; Parrini et al,
2002). Since the data of Figure 2C suggest that Nischarin
may bind preferentially to active PAK1, this implies that
the binding of an active Rac1 to PAK1 should enhance the
Nischarin/PAK1 interaction. Further, since introduction
of a Y40C effector site mutation into Rac1 disrupts Rac1
binding to PAK1 (Westwick et al, 1997), this should reduce
Rac’s ability to enhance PAK1/Nischarin complex formation.
As predicted, coexpression of active Rac1Q61L led to the
enhancement of Nischarin co-immunoprecipitation with
PAK1 (by about 3.5-fold) (Figure 6A and Supplementary
Figure 4). By contrast, coexpression of mutant Rac1Q61L/
40C resulted in less co-immunoprecipitation of PAK1
with Nischarin as compared to Rac1Q61L (Figure 6B).
These data demonstrate that Rac activation of PAK1
enhances the formation of the Nischarin/PAK1 complex and
this is dependent on the ability of Rac to bind to PAK1.
Further, the presence of Nischarin does not inhibit the ability
of PAK1 to bind Rac1, rather these proteins can form a
tripartite complex.
Figure 6 Effects of Rac and of PAK conformation on PAK/Nischarin binding. (A) Rac enhances Nischarin/PAK1 interaction. Myc-Nischarin
and Myc-PAK1 were cotransfected into Cos-7 cells with HA-Rac1Q61L or pCGN vector control. After immunoprecipitation of PAK1 with
polyclonal PAK1 antibody (N20), the levels of co-immunoprecipitating Myc-Nischarin were determined by Western blotting and were
quantified on a Fluor-S MultiImager (Bio-Rad) and normalized to the vector control. The error bars show standard deviation (N¼ 6). (B)
Rac40C is less effective at promoting PAK–Nischarin interaction. Myc-Nischarin and V5-PAK1 were cotransfected with HA-Rac1Q61L or HA-
Rac1Q61L/40C. Myc-Nischarin was immunoprecipitated from cytoplasmic lysates and immunoblots were performed to detect the indicated
epitopes. (C) Rac increases the binding of both WTand kinase-dead PAK1 to Nischarin. Myc-Nischarin was coexpressed with HA-Rac1Q61L and
with V5-PAK1 or V5-PAK1-K299R. The lysates were immunoprecipitated with anti-Myc and the immunoprecipitates blotted with antibodies to
the indicated epitopes. (D) Nischarin binds to the open conformation of PAK1. Cos-7 cells were transfected with Myc-Nischarin or pcDNA and
V5-PAK1, V5-PAK1-L107F, V5-PAK1-K299R or V5-PAK1-K299R-L107F. PAK1 was immunoprecipitated with the anti-V5 antibody. The input and
immunoprecipitates were blotted for the respective epitope tags of the transfected proteins.
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While the data of Figures 6A and B indicate that the
activation PAK1 facilitates the interaction of Nischarin with
PAK1’s kinase domain, it does not determine whether kinase
activity itself is necessary for this interaction. Activation of
group 1 PAKs involves a relaxation of the association between
the N-terminal autoinhibitory domain and the C-terminal
kinase domain (Lei et al, 2000; Parrini et al, 2002); thus,
the ‘open’ conformation may be the preferred configuration
for Nischarin binding. This concept was tested in two ways.
First, active Rac was coexpressed with Nischarin and with
either WT PAK1 or the K299R mutant of PAK1 that lacks
kinase activity. As seen in Figure 6C, active Rac strongly
promoted Nischarin binding to both forms of PAK1. Second,
we examined the effect of the L107F mutation that inhibits the
association of the regulatory and kinase domains of PAK1. As
seen in Figure 6D, the presence of this mutation increased the
binding of Nischarin to both WT PAK1 and K299R PAK1.
Thus these data strongly suggest that Nischarin binds to the
‘open’ conformation of PAK1, but that kinase activity per se is
not required.
The interaction between Nischarin and PAK1 is direct
As shown above, PAK and Nischarin clearly exist in intracel-
lular complexes. However, the interaction may be mediated
by direct contact between these two proteins or through an
unknown intermediary protein. To determine if Nischarin
directly interacts with PAK1, Nischarin’s N-terminus (1–
802)-6xHis was expressed in an Escherichia coli-based tran-
scription/translation system. This prokaryotic system should
not contain any proteins that might mediate the PAK1/
Nischarin interaction. Expression of a modified transcription
factor TGV-6xHis (Ye and Juliano, 2002) was used as a
negative control. Incubation of GST-PAK1-248-545-K299R
with N-terminus-6xHis resulted in the formation of specific
complexes, while nonspecific interactions were absent
(Figure 7A). These data support the idea that the complex
formed by Nischarin and PAK1 is mediated by a direct
interaction between these two proteins. Similar results were
obtained when the Nischarin N-terminus was expressed in a
eukaryotic transcription–translation system and allowed to
interact with GST-PAK1. Further, while WT GST-PAK1 bound
Nischarin, full-length kinase-dead PAK1 did not, further
supporting the hypothesis that PAK must be able to attain
its ‘open’ conformation to bind Nischarin (Figure 7B).
Nischarin interacts with group 1 and 2 PAKs
To examine the potential of Nischarin to interact with other
PAK isoforms, human PAK1, PAK4 and PAK5 were coex-
pressed in Cos-7 cells with Nischarin linked to EGFP at its
C-terminus. Immunoprecipitation of PAK1, PAK4 and PAK5
by their Myc tags co-precipitated the coexpressed Nischarin-
EGFP, without precipitating EGFP itself (Figure 8). Thus,
Nischarin interacts with PAK isoforms from both groups 1
and 2.
Discussion
Cell migration is an intricate process involving several signal
transduction pathways, including a key role for members of
the PAK family of kinases (Bokoch, 2003). Thus it is impor-
tant that PAK activity in various regions of the cell be
orchestrated in a coordinated manner. As described above,
Figure 7 In vitro binding of Nischarin and PAK1. (A) In vitro
binding of Nischarin N-terminus to GST-PAKs. The 6xHis-tagged
N-terminus and the transcription factor TGV-6xHis were expressed
in the E. coli ExpresswayTM In Vitro Protein Synthesis System.
Lysates containing the N-terminus-6xHis or TGV-6xHis were incu-
bated with GST-PAK1-248-545-K299R or GST and bound proteins
were isolated on glutathione–Sepharose 4B beads. The immuno-
blots were probed with anti-6xHis and anti-GST monoclonal anti-
bodies. (B) Binding of rabbit reticulocyte expressed Nischarin N-
terminus to GST-PAKs. The N-terminus Myc fragment was ex-
pressed in the TnTs rabbit reticulocyte transcription/translation
system. Binding to GST fusion protein was conducted as in (A). The
immunoblots were probed with anti-Myc and anti-GST monoclonal
antibodies.
Figure 8 Interaction of Nischarin with PAK4 and PAK5. Nischarin-
EGFP or EGFP and Myc-PAK1, Myc-PAK4 or Myc-PAK5 were coex-
pressed in Cos-7 cells. The PAK proteins were immunoprecipitated
from lysates via the Myc epitope. The immunoprecipitates were
immunoblotted for the presence of Myc and EGFP epitopes. The left
column demonstrates binding of Nischarin-EGFP to PAK1, PAK4
and PAK5 (upper panel), whereas EGFP alone did not co-precipitate
with the various PAKs (mid-panel). The right panels are loading
controls.
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the novel protein Nischarin potently inhibits both PAK activ-
ity and cell migration. Therefore, understanding the relation-
ship between Nischarin and PAK family kinases may provide
key insights into the regulation of motility.
The N-terminal domain (1–802) of Nischarin interacts with
the C-terminal (248–545) kinase domain of PAK1. Several
independent sites within the N-terminus are able to bind
PAKs to some degree, raising the possibility that a single
molecule of Nischarin may be able to bind more than one
molecule of PAK. However, the precise stoichiometry of
Nischarin–PAK binding has not yet been established. The
existence of several distinct binding regions on Nischarin is
not unusual for such a large, complex protein; for example,
the regulator protein FIP200 binds to focal adhesion kinase
via several distinct segments (Abbi et al, 2002). It should be
noted that IRAS, the human ortholog of Nischarin, binds to
the adaptor protein IRS-4 (Sano et al, 2002), but the con-
sequences of this are unclear.
Nischarin not only binds to PAK1 but also strongly inhibits
PAK kinase activity. PAK1 binds Nischarin via its kinase
domain and the interaction is enhanced when PAK1 is in its
activated or ‘open’ conformation, as in the presence of
activated Rac. However, the interaction of Nischarin with
PAK1 is not dependent on kinase activity per se, but rather on
PAK1 being in the open configuration. There are a number of
other proteins that bind to PAKs and affect their function.
Most of these proteins interact with the PAK regulatory
domain and alter PAK’s conformation or cellular localization
(Bokoch et al, 1996; Galisteo et al, 1996; Manser et al, 1998;
Puto et al, 2003); however, the PAK kinase domain can also
bind proteins, including the Raf-1 and LIM kinases (Edwards
et al, 1999; Zang et al, 2002).
In addition to the autoinhibitory role of the PAK N-termi-
nus (Parrini et al, 2002), several other mechanisms for
negative regulation of PAK kinase activity are known. Thus
various kinases, such as PKA, can inactivate PAKs by phos-
phorylation of key residues (Howe and Juliano, 2000), while
certain phosphatases can inactivate PAKs through depho-
sphorylation (Koh et al, 2002). The mechanism underlying
Nischarin’s inhibition of PAK activity has not yet been
worked out in detail. However, our initial results suggest
that Nischarin can hinder the autophosphorylation and acti-
vation of PAK1 and interrupt PAK’s ability to phosphorylate
substrates. In contrast, Nischarin does not seem to be a very
good substrate for PAK, and thus it is less likely that
Nischarin blocks PAK1 by simply competing with other
substrates for phosphorylation.
Nischarin’s ability to inhibit PAK kinase activity is closely
correlated with its effects on cell migration. Thus, although
the N-terminal domain of Nischarin binds well to PAK1, it has
no effect on either cell migration or kinase activity, nor does
the isolated C-terminal domain; full-length Nischarin is re-
quired to inhibit in both instances. Reduction of endogenous
Nischarin levels using RNA interference reinforces the con-
cept that Nischarin regulates cell migration, most likely by
affecting PAK activity. Thus, while overexpression of
Nischarin inhibits PAK kinase activity and cell migration,
siRNA-mediated reduction of endogenous Nischarin levels
enhances migration, as well as increasing the activity of
endogenous PAK.
It is interesting that neither the full N-terminus (1–802) nor
the previously identified integrin-binding domain (434–581)
of Nischarin (Alahari et al, 2000) is able to inhibit cell
migration significantly. This emphasizes that Nischarin’s
effects on migration are primarily mediated through inhibit-
ing PAK rather than through binding to integrins and blocking
their function. However, by associating both with integrins
and with PAKs, Nischarin might allow a focusing of PAK
inhibition in certain regions of the cell.
Since Nischarin regulates PAK effects on cell migration,
one would expect these molecules to colocalize in membrane
protrusions involved in motility. Thus, in actively spreading
fibroblasts, PAK1 and Nischarin colocalize in membrane
ruffles, structures known to be involved in cell migration
(Sastry and Burridge, 2000). Nischarin shows stronger mem-
brane colocalization with a constitutively active PAK1 mutant
than with WT PAK1, and conversely Nischarin does not
display membrane colocalization with kinase-dead PAK1.
Interestingly, examination at higher power suggests that the
area of PAK/Nischarin overlap is behind the leading edge of
the membrane protrusion, while PAK alone is enriched in the
edge. This observation is consistent with the idea that
Nischarin binds to and inhibits PAK after PAK has been
activated in sites of membrane protrusive activity. As we
described previously, although Nischarin binds the a5b1
integrin, Nischarin does not localize to focal adhesions
(Alahari et al, 2000). However, certain other proteins that
strongly interact with integrins do not localize in focal adhe-
sions (Hemler, 2001; Degani et al, 2002) and Nischarin seems
to follow this pattern, localizing instead in more dynamic
membrane protrusions. Nonetheless, the presence of the a5b1
integrin affects the binding of Nischarin to PAKs, suggesting a
functional interconnection between Nischarin’s ability to
bind integrins and its association with PAKs.
While it is clear that Nischarin plays a key role in the
regulation of PAK activity and the control of cell migration,
the precise mechanisms involved are not yet fully under-
stood. One hypothesis that is consistent with current data is
as follows. In migrating cells active PAK is recruited to
membrane protrusions (ruffles/lamellipodia/filopodia)
where it contributes to enhanced actin filament formation
and reduced contractility. However, in order for stable adhe-
sions to form, contractility must increase (Sastry and
Burridge, 2000), and thus PAK activity must be turned off.
We hypothesize that Nischarin (perhaps in association with
a5b1) is also recruited to membrane protrusions. There,
Nischarin can bind active PAK, reducing its kinase activity,
permitting increased contractility and allowing adhesive con-
tacts to form. As mature adhesive contacts develop, PAK is
inactivated and the Nischarin is released, allowing the pro-
cess to recycle. Thus, Nischarin may be a key physiological




Full-length mouse Nischarin cDNA, all Nischarin deletion mutants
and b-galactosidase were expressed from pcDNA3.1 Bþ Myc/His
(Invitrogen). Nischarin was also expressed from pEGFP-N1 vector
(Clontech). Full-length human PAK1 (provided by J Chernoff), its
regulatory domain (1–248), its kinase domain (248–545), the
T423E, K299R, L107F and K299R/L107F mutants, the autoinhibitory
domain (AID) and b-galactosidase were expressed from pcDNA3.1
Bþ V5/His (Invitrogen). For the in vitro binding studies, GST-tagged
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PAK1, PAK1-K299R and GST-PAK1-248-545-K299R were expressed
from the bacterial expression vector pGEX-6P-3 (Amersham
Biosciences). For expression in a bacterial system, the cDNA for
the Nischarin N-terminus was inserted into the pET30a (þ ) vector
(Novagen). As a control, a fusion protein (TGV-6xHis) containing
the GAL4 DNA-binding domain was used (Ye and Juliano, 2002).
Myc-tagged PAK4 and PAK5 (provided by A Minden) were
expressed from the vectors pSRa3 and pCAN-Myc1, respectively
(Dan et al, 2002). HA-tagged Rac1Q61L and HA-Rac1Q61L/40C
(provided by C Der) were expressed from the pCGN vector.
Immunoprecipitation
For Nischarin/PAK binding, Cos-7 cells were transfected with 1mg
each of Nischarin and PAK1 plasmids using FuGENE 6 (Roche).
After 48 h, the cells were lysed in an NP-40 lysis buffer (50 mM Tris–
HCl pH 7.5, 250 mM NaCl, 5 mM EDTA, 0.1% NP-40) with protease
and phosphatase inhibitors. The lysates were incubated with anti-
Myc antibody 9E10 (Covance), anti-V5 antibody (Stratagene) or
anti-PAK1 (N-20) (Santa Cruz Biotechnology) at 41C for 2 h. The
immune complexes were precipitated with protein G–Sepharoses
and the precipitates were resolved on a 4–20% gradient gel. The
immunoprecipitated proteins were detected with the antibodies
used for immunoprecipitation or anti-HA antibody HA.11 (Cov-
ance). To examine the interaction of endogenous Nischarin and
PAK1, PC12 cells were lysed and 15 mg of the cleared supernatant
was incubated with 100 mg of agarose-conjugated anti-PAK1 anti-
body (N20) or agarose-conjugated control rabbit IgG overnight at
41C. The immunoprecipitates were immunoblotted as above for
endogenous Nischarin with a mouse anti-Nischarin monoclonal
antibody supernatant (gift of Dr R Campos, Becton-Dickinson Inc.)
or control mouse IgG, and for endogenous PAK with N20.
In vitro expression and binding of Nischarin
Nischarin N-terminus-6xHis or TGV-6xHis were produced in the
ExpresswayTM (Invitrogen) bacterial cell-free system, and the
cleared supernatants were used for binding studies. The rabbit
reticulocyte-based TnTs Quick Coupled Transcription/Translation
System (Promega) was used to express the N-terminus of Nischarin
in a eukaryotic cell-free system. The DH5a E. coli strain transformed
with pGEX-6P-3 vectors was used for expression of PAK1-GST
fusion proteins. Only the kinase-dead form of the PAK1 kinase
domain was used because the active kinase is toxic to E. coli. A
10 mg portion of the GST fusion proteins was incubated with 50 ml
generated from either the TnTs System or the ExpresswayTM
System brought to a total volume of 300 ml with 0.1% NP-40 lysis
buffer. The samples were incubated for 1 h at 301C at 500 rpm and
the proteins were pulled down with glutathione–Sepharose 4B.
Kinase assays
For evaluating PAK activity, Cos-7 cells were transfected with V5-
PAK1 and various Myc-Nischarin constructs, or with Myc-b-gal.
After 24 h of incubation in DMEM containing 10% FBS, the medium
was replaced with serum-free DMEM for another 24 h. Cells were
stimulated with 10% FBS for 15 min, and lysed in modified RIPA
buffer with protease inhibitors. For immunoprecipitation, about
900 mg of lysate was incubated with 9 mg of anti-V5 antibody
(Invitrogen) for 2 h at 41C, then precipitated with protein A–
Sepharose. Kinase assays were carried out for 5 or 30 min at 301C in
50ml of kinase reaction buffer containing 5–15 mg of myelin basic
protein, 1 mM ATP and 10mCi [32P]ATP. The reaction was stopped
with 6 sample buffer. The samples were electrophoresed on 15%
SDS–PAGE gels, stained with Coomassie blue, dried and exposed to
X-ray films. In some experiments, constitutively active V5-PAK-
T423E and Myc-Nischarin or Myc-b-gal were used; the cells
expressing these constructs were maintained in 0.5% FBS-contain-
ing medium for 48 h, and kinase assays were performed as
described above. As a negative control, kinase-dead V5-PAK-
K299R was used. Similar assays were used to measure the activity
in immunoprecipitates of endogenous PAK from PC12 cells. Activity
of JNK was evaluated as described (Alahari, 2003).
Transwell cell migration assay
Haptotactic cell migration assays were performed essentially as
described (Alahari et al, 2000). Briefly, CHO B2a27 cells were
transiently transfected with constitutively active PAK (V5-PAK-
T423E) or with V5-PAK-K299R, plus full-length or truncated forms
of Nischarin. A pRC b-gal plasmid (Stratagene) (1 mg) was used as a
marker. The underside of the transwell was coated with fibronectin
and 200 000 cells were added to the upper surface. The b-
galactosidase-positive cells that migrated through the membrane
during an overnight incubation were counted by staining for b-gal.
The ratio of migrant transfected cells to total transfected cells was
normalized to the vector control. PC12 cells were transfected with
b-gal plasmid and 150 or 300 nM of rat Nischarin siRNA or control
siRNA, using Lipofectamine 2000. In some cases, 1mg of a plasmid
expressing the PAK1 autoinhibitory domain (AID) was also
transfected. The underside of the transwell was coated with
collagen and 300 000 cells were added to the upper surface. The
migrant fraction of transfected cells was evaluated as described
above.
Confocal microscopy
The basic procedures have been described previously (Alahari et al,
2000). Briefly, rat embryonic fibroblasts were transiently transfected
with 0.2mg of GFP or GFP-Nischarin along with 1 mg of Myc-PAK1 or
mutated versions of PAK1. After 24 h of transfection, cells were
serum starved overnight in 1% BSA-containing DMEM. Cells were
trypsinized and replated on fibronectin-coated coverslips for
various times in the presence of 10% FBS-containing DMEM. The
cells were washed with PBS, fixed in 0.37% formaldehyde,
permeabilized in 1% Triton X-100 and blocked in BSA for 1 h at
room temperature. The coverslips were stained with anti-Myc
antibody for 1 h at room temperature followed by incubation with
TRITC-conjugated secondary antibody. The coverslips were ob-
served on an Olympus Confocal FV300 fluorescent microscope with
60 oil immersion objective; images were acquired by using
Olympus Fluoview software.
Reduction of endogenous Nischarin by siRNA
A 21 base pair siRNA for rat Nischarin, rCrCUrCrGUrGrCrArCr
CUUrGrArCrCUrGTT, as well as a ‘scrambled’ siRNA and an siRNA
for human MDR-1, both used as controls, were synthesized by
Proligo Inc. To determine the effectiveness of the Nischarin siRNA,
rat PC12 cells were transfected using Lipofectamine 2000 with the
plasmid pcDNA-CD4 and with siRNA at a concentration of 150 nM.
At 48 h after transfection, cells were detached with trypsin–EDTA
and anti-CD4-coated magnetic beads (Dynal) were used to enrich
the transfected cells by magnetic selection. The cells were lysed in
RIPA buffer and the soluble supernatants were used for immuno-
blotting. Nischarin levels were determined with an anti-Nischarin
antibody. Cell migration experiments were carried out after similar
transfection with Nischarin siRNA or control siRNAs (see above)
with b-gal as a marker. Experiments involving the effect of siRNA
on protein kinase activity did not involve any enrichment
procedure.
Supplementary data
Supplementary data are available at The EMBO Journal Online.
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